about
Intrinsically unstructured domain 3 of hepatitis C Virus NS5A forms a "fuzzy complex" with VAPB-MSP domain which carries ALS-causing mutationsDiacylglycerol acyltransferase-1 localizes hepatitis C virus NS5A protein to lipid droplets and enhances NS5A interaction with the viral capsid coreSafety and efficacy of daclatasvir in the management of patients with chronic hepatitis CDaclatasvir: potential role in hepatitis CThe crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitorsDirect binding of a hepatitis C virus inhibitor to the viral capsid proteinMetabolism of phosphatidylinositol 4-kinase IIIα-dependent PI4P Is subverted by HCV and is targeted by a 4-anilino quinazoline with antiviral activityA quantitative high-resolution genetic profile rapidly identifies sequence determinants of hepatitis C viral fitness and drug sensitivityA new stochastic model for subgenomic hepatitis C virus replication considers drug resistant mutantsDEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5ANS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection.Hepatitis C virus nonstructural protein 5A: biochemical characterization of a novel structural class of RNA-binding proteinsPreclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action.Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors.Hepatitis C virus NS5A activates the mammalian target of rapamycin (mTOR) pathway, contributing to cell survival by disrupting the interaction between FK506-binding protein 38 (FKBP38) and mTORInhibition of dengue virus by targeting viral NS4B proteinResistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replicationExpanding the proteome of an RNA virus by phosphorylation of an intrinsically disordered viral protein.Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures.Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052Hepatitis C virus experimental model systems and antiviral drug research.Profile of alisporivir and its potential in the treatment of hepatitis C.Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA.Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.Resistance patterns associated with HCV NS5A inhibitors provide limited insight into drug binding.In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A.Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides.Natural compounds isolated from Brazilian plants are potent inhibitors of hepatitis C virus replication in vitro.Resistance analysis and characterization of a thiazole analogue, BP008, as a potent hepatitis C virus NS5A inhibitorIdentification of novel anti-hepatitis C virus agents by a quantitative high throughput screen in a cell-based infection assay.Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvirEfficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells.Resistance studies of a dithiazol analogue, DBPR110, as a potential hepatitis C virus NS5A inhibitor in replicon systems.Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir.Approaches to hepatitis C treatment and cure using NS5A inhibitorsViral tricks to grid-lock the type I interferon system.Discovery of hepatitis C virus NS5A inhibitors as a new class of anti-HCV therapy.
P2860
Q21560973-959BFDCE-375A-42A5-9B3D-F04F552CE862Q24318808-5DAB3334-E610-4B67-8766-564BCE393AEEQ26745769-88E26F56-05CE-4C63-A329-569AF7047696Q27012741-736A6287-A2C1-4E6A-92F1-01F361458CCBQ27682272-6CFCBB41-52FC-450A-A69E-9E3C68BC9BACQ28481306-8565467F-F217-4E3D-AFDC-0039F0BACACCQ28481438-2365D326-7E3B-459C-8E56-4262FC4487DBQ28537708-B0232DB9-5988-4CFA-B69A-77E5B662FFFFQ28541048-6C6384D9-958E-49B9-8707-45BA488103C6Q28748683-32D73EA4-FAF4-440E-8014-D47B5E81ADC7Q30352718-BB756774-5F21-4872-8523-CC67B664154AQ33711743-F5185FA4-DFF3-464B-B186-6F0ACE3DEDE2Q33798031-2E3DA196-E807-4835-A74D-9A4CA3CD7376Q33878202-7A363637-5CC9-4D91-978E-8825F57F909BQ33934312-201FD83F-7DFC-4187-A368-D2A7A51C2C3CQ33966987-E8EDE5FD-4862-4C41-B511-27FD0C93B6F9Q34002195-ABCD79FB-A85A-4711-BE20-879E4C3AC995Q34022926-6442185B-4A39-4EAE-8585-09A214F81F70Q34045444-3A83879C-E986-4D0A-9E00-40A59D7113F0Q34107289-39B136CB-CA42-4FB5-8A4C-739BEB55B277Q34185327-F7F59FF4-8E3C-4CD4-8D00-A6E027332263Q34185949-CC5DDC27-571A-444A-9733-FA3F50CCAB04Q34235286-99BFC2DC-2C31-4390-81D8-F9495778844BQ34329744-9E4C4AFE-EF6C-4C6E-ACCF-82F75510CD0FQ34416582-FD3FBFC9-B54C-461B-B6D1-5D9EC10DFE43Q34489239-E5315FBB-23AE-4D83-A9D2-7D70FF7F95EEQ34580799-BDE30207-F61D-4C75-842D-2A7BC04373BDQ34634693-9308C6D7-6CD2-4361-A383-0A4897D72B0DQ34634791-9D20D8C4-CC56-4235-8FF5-292E2F7CF5EDQ35070501-0D853F82-D962-41FE-A90C-A04904058F6FQ35087842-A29CB993-6D28-4CAC-9F94-00058D7584B7Q35666596-7C6E98D7-6E72-43C3-B0A3-D6067399B354Q35826848-CE770B2E-586A-48F9-BCF3-19D40693EE56Q36276803-2970D8DE-1308-4F55-A62E-0551430AFDF6Q36276817-5FE86430-37FE-4D5B-96FA-08095B949579Q36558519-57018841-54D9-4DE1-BCBA-D1D131E52F44Q36785846-DC4F9479-F08F-46B8-87E7-8C960C9F5EF7Q37630422-A12E2C80-7B94-48B4-88C9-0C559F188C1FQ37764230-DECCA5F4-8BF2-4A52-BC12-795B89732800Q37942777-B0195143-80A4-4D1C-8BFA-FB387627660A
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Identification of Hepatitis C Virus NS5A Inhibitors
@ast
Identification of Hepatitis C Virus NS5A Inhibitors
@en
Identification of Hepatitis C Virus NS5A Inhibitors
@nl
type
label
Identification of Hepatitis C Virus NS5A Inhibitors
@ast
Identification of Hepatitis C Virus NS5A Inhibitors
@en
Identification of Hepatitis C Virus NS5A Inhibitors
@nl
prefLabel
Identification of Hepatitis C Virus NS5A Inhibitors
@ast
Identification of Hepatitis C Virus NS5A Inhibitors
@en
Identification of Hepatitis C Virus NS5A Inhibitors
@nl
P2093
P2860
P3181
P356
P1433
P1476
Identification of Hepatitis C Virus NS5A Inhibitors
@en
P2093
Denis R St Laurent
Donald O'Boyle
Jeffrey L Romine
Julie A Lemm
Lawrence B Snyder
Mengping Liu
Michael H Serrano-Wu
Milind S Deshpande
Nicholas A Meanwell
P2860
P304
P3181
P356
10.1128/JVI.01360-09
P577
2010-01-01T00:00:00Z